Valuation: SurModics

Market Cap 427M 370M 349M 317M 595M 40.96B 599M 4.17B 1.61B 20.78B 1.61B 1.57B 66.06B P/E 2023
-292x
P/E 2024 -47.3x
Enterprise Value 420M 364M 344M 312M 585M 40.3B 589M 4.11B 1.58B 20.45B 1.58B 1.54B 65B EV / Sales 2023
3.33x
EV / Sales 2024 4.33x
Free-Float
99.63%
Yield 2023 *
-
Yield 2024 -
1 year 25.87
Extreme 25.87
43
3 years 25.17
Extreme 25.17
43
5 years 16
Extreme 16
59.62
10 years 16
Extreme 16
82.35
Manager TitleAgeSince
Chief Executive Officer 67 19/11/2025
Director of Finance/CFO 53 19/11/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 19/11/2025
Director/Board Member 53 19/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
19/11/25 Issuer sale

Executive/Senior Manager

171,148 1.1970%
19/11/25 Issuer sale

Director

35,847 0.2507%
19/11/25 Issuer sale

Controller/Auditor

24,311 0.1700%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-.--%+34.48%+22.35% 615M
+1.12%-4.84%-22.91%+0.43% 176B
+3.12%-0.39%-0.24%+14.45% 116B
+1.45%-1.43%+7.84%+84.32% 61.36B
+0.31%-3.49%+3.90%+34.63% 49.42B
+2.85%-0.99%-2.10%-30.88% 48.44B
+1.99%-3.66%+11.10%-16.61% 31.33B
+0.18%-10.93% - - 28.54B
+2.59%+4.48%+40.12%-10.73% 24.37B
-0.24%-2.99%-10.45%+2.52% 21.57B
Average +1.38%-3.41%+6.86%+11.16% 55.84B
Weighted average by Cap. +1.67%-3.36%-4.49%+12.14%

Financials

2023 2024
Net sales 133M 115M 108M 98.36M 185M 12.71B 186M 1.29B 499M 6.45B 498M 487M 20.49B 126M 109M 103M 93.53M 175M 12.08B 177M 1.23B 474M 6.13B 474M 463M 19.49B
Net income -1.54M -1.33M -1.26M -1.14M -2.14M -147M -2.15M -15M -5.78M -74.68M -5.77M -5.64M -237M -11.54M -10M -9.44M -8.56M -16.06M -1.11B -16.18M -113M -43.43M -561M -43.35M -42.39M -1.78B
Net Debt -12.1M -10.49M -9.9M -8.98M -16.84M -1.16B -16.96M -118M -45.54M -588M -45.45M -44.45M -1.87B -6.87M -5.95M -5.62M -5.1M -9.56M -658M -9.63M -67.09M -25.85M -334M -25.8M -25.23M -1.06B
Logo SurModics
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Employees
389
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SRDX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!